Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A fresh comparison frames Pfizer and AbbVie as income-focused options for 2026, pointing to their dividend levels as a key differentiator versus the broader market.
THE APEX TIMES
THE APEX TIMES
In retirement, Bill Rutherford, a long-time finance executive at HCA Healthcare, is turning from running financial operations to serving on boards, while emphasizing how partnerships across care settings can improve outcomes and reduce cost pressures.
THE APEX TIMES
The health insurer and pharmacy retailer said it was recognized for building organization-wide AI literacy and colleague confidence through its AI Learning Academy.
THE APEX TIMES
A U.S. lawsuit filed in New Jersey underscores how the fastest-growing weight-loss category is shifting from marketing claims to legal disputes over future earnings in the GLP-1 era.
THE APEX TIMES
A new comparison of Pfizer and BioNTech, two firms tied to the COVID-19 vaccine partnership, points to a shared challenge: how to sustain growth as pandemic-era demand fades. The article discusses their Q2 2026 earnings and highlights major strategic announcements, but does not provide enough detail to determine which company has the clearer path forward.
THE APEX TIMES
The U.K. regulator has authorized Eli Lilly’s oral weight-management and type 2 diabetes drug, making Britain the first country in Europe to clear the medicine, according to a market report.
THE APEX TIMES
The UK’s medicines regulator, MHRA, has given Lilly’s Foundayo a regulatory green light, while the European Union review is still ongoing. The move is expected to raise the competitive stakes in a crowded obesity and weight-management market dominated by injectable medicines and expanding pipeline bets.
THE APEX TIMES
Veeva Systems said Eli Lilly has committed to deploy Vault CRM globally, indicating continued investment in cloud-based tools that manage sales and customer engagement in life sciences.
THE APEX TIMES
Eli Lilly’s LLY shares have reflected investor enthusiasm for GLP-1 medicines, and a televised discussion highlighted a view that the market’s momentum may have years left, not quarters.
